Cargando…

Increased Risk of Virologic Rebound in Patients on Antiviral Therapy with a Detectable HIV Load <48 Copies/mL

We investigated the independent effects of HIV-1 ”target not detected” measurements versus those that were detectable but below the limit of quantification by Taqman RT-PCR assay on subsequent viral rebound as there are conflicting data regarding the clinical implications of arbitrary or isolated lo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Henrich, Timothy J., Wood, Brian R., Kuritzkes, Daniel R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2012
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3499490/ https://www.ncbi.nlm.nih.gov/pubmed/23166820 http://dx.doi.org/10.1371/journal.pone.0050065

Ejemplares similares

Real-Time Predictions of Reservoir Size and Rebound Time during Antiretroviral Therapy Interruption Trials for HIV
por: Hill, Alison L., et al.
Publicado: (2016)

Correction: Real-Time Predictions of Reservoir Size and Rebound Time during Antiretroviral Therapy Interruption Trials for HIV
por: Hill, Alison L., et al.
Publicado: (2017)

HCV Viral Load Greater Than 1000 IU/ml at Time of Virologic Failure in Direct-Acting Antiviral-Treated Patients
por: Morgan, Jake R., et al.
Publicado: (2021)

HIV-1 Virologic Rebound Due to Coadministration of Divalent Cations and Bictegravir
por: Rock, Alex E., et al.
Publicado: (2020)

75. High Rates of Virologic Suppression with DTG/3TC in Newly Diagnosed Adults with HIV-1 Infection and Baseline Viral Load >500,000 c/mL: 48-Week Subgroup Analysis of the STAT Study
por: Rolle, Charlotte-Paige M, et al.
Publicado: (2021)

Intradermal injection of a Tat Oyi-based therapeutic HIV vaccine reduces of 1.5 log copies/mL the HIV RNA rebound median and no HIV DNA rebound following cART interruption in a phase I/II randomized controlled clinical trial
por: Loret, Erwann P., et al.
Publicado: (2016)

Erratum to: Intradermal injection of a Tat Oyi-based therapeutic HIV vaccine reduces of 1.5 log copies/mL the HIV RNA rebound median and no HIV DNA rebound following cART interruption in a phase I/II randomized controlled clinical trial
por: Loret, Erwann P., et al.
Publicado: (2016)

Nanostructured Optical Photonic Crystal Biosensor for HIV Viral Load Measurement
por: Shafiee, Hadi, et al.
Publicado: (2014)

Cerebrospinal fluid biomarkers in patients with plasma HIV RNA below 20 copies/mL
por: Calcagno, Andrea, et al.
Publicado: (2014)

Four-drugs regimen containing raltegravir is highly effective in HIV patients starting therapy with >500,000 copies/mL viral load
por: Sterrantino, Gaetana, et al.
Publicado: (2014)

Durability of lopinavir/ritonavir dual-therapies in individuals with viral load <50 copies/mL in the observational setting
por: Gianotti, Nicola, et al.
Publicado: (2014)

Impact of CD4 and CD8 dynamics and viral rebounds on loss of virological control in HIV controllers
por: Chereau, Fanny, et al.
Publicado: (2017)

Expression of type I interferon-associated genes at antiretroviral therapy interruption predicts HIV virological rebound
por: Zacharopoulou, P., et al.
Publicado: (2022)

Markers of CNS Injury in Adults Living With HIV With CSF HIV Not Detected vs Detected <20 Copies/mL
por: Farhadian, Shelli F, et al.
Publicado: (2019)

SARS-CoV-2 virologic rebound with nirmatrelvir-ritonavir therapy
por: Edelstein, Gregory E., et al.
Publicado: (2023)

HIV virological rebounds but not blips predict liver fibrosis progression in antiretroviral-treated HIV/hepatitis C virus-coinfected patients
por: Cooper, C, et al.
Publicado: (2015)

Virological and clinical rebounds of COVID-19 soon after nirmatrelvir/ritonavir discontinuation
por: Antonelli, Guido, et al.
Publicado: (2022)

Risk of HIV viral rebound in HIV infected patients on direct acting antivirals (DAAs) treatment for HCV
por: Morsica, Giulia, et al.
Publicado: (2022)

COVID-19 redux: clinical, virologic, and immunologic evaluation of clinical rebound after nirmatrelvir/ritonavir
por: Epling, Brian P., et al.
Publicado: (2022)

Impact of HLA Class I Alleles on Timing of HIV Rebound After Antiretroviral Treatment Interruption
por: Park, You Jeong, et al.
Publicado: (2017)

SARS-CoV-2 rebound with and without antivirals
por: Petrosillo, Nicola
Publicado: (2023)

To rebound or not to rebound
por: Stahl, Bethany A, et al.
Publicado: (2017)

Changing antiretrovirals whilst viral load <50 copies/ml and relationship with CD4 count changes
por: Mocroft, A
Publicado: (2010)

The PROTEA trial: darunavir/ritonavir with or without nucleoside analogues, for patients with HIV-1 RNA below 50 copies/mL
por: Antinori, Andrea, et al.
Publicado: (2014)

Modest deviations from optimal adherence to antiretroviral therapy promote residual HIV-1 replication in the absence of virological rebound in plasma
por: Pasternak, Alexander O, et al.
Publicado: (2011)

Virologic Failure of Protease Inhibitor-Based Second-Line Antiretroviral Therapy without Resistance in a Large HIV Treatment Program in South Africa
por: Levison, Julie H., et al.
Publicado: (2012)

The MONET trial: correlation between Hepatitis C coinfection and HIV RNA responses during darunavir/ritonavir monotherapy, for patients with HIV RNA <50 copies/mL at baseline
por: Arribas, Jose R, et al.
Publicado: (2010)

Nirmatrelvir–Ritonavir and Viral Load Rebound in Covid-19
por: Anderson, Annaliesa S., et al.
Publicado: (2022)

Time spent with HIV-RNA ≤ 200 copies/ml in a cohort of people with HIV during the U=U era
por: Madeddu, Giordano, et al.
Publicado: (2021)

Virologic failure after 48 weeks of raltegravir-based regimen in low HIV-1 incidence setting
por: Chehadeh, Wassim, et al.
Publicado: (2020)

Alternative methods to analyse the impact of HIV mutations on virological response to antiviral therapy
por: Wittkop, Linda, et al.
Publicado: (2008)

Predictive factors of viral load high-risk events for virological failure in HIV/AIDS patients receiving long-term antiviral therapy
por: Qin, Shanfang, et al.
Publicado: (2021)

Sustained Virologic Suppression With Dolutegravir/Lamivudine in a Test-and-Treat Setting Through 48 Weeks
por: Rolle, Charlotte-Paige, et al.
Publicado: (2023)

Episomal Viral cDNAs Identify a Reservoir That Fuels Viral Rebound after Treatment Interruption and That Contributes to Treatment Failure
por: Sharkey, Mark, et al.
Publicado: (2011)

1278. Real World Treatment Experience of Single Tablet Dolutegravir/Lamivudine in Those Naïve to Treatment with Baseline Viral Loads ≥ 100,000 copies/mL in the US
por: Benson, Paul, et al.
Publicado: (2022)

Antiviral Mechanisms: Perspectives in Virology, Volume IX
por: Darling, Tom
Publicado: (1976)

Functional genomics in virology and antiviral drug discovery
por: DeFilippis, Victor, et al.
Publicado: (2003)

Determinants of viral load rebound on HIV/AIDS patients receiving antiretroviral therapy: results from South Africa
por: Shoko, Claris, et al.
Publicado: (2018)

Raltegravir plus abacavir/lamivudine in virologically suppressed HIV-1-infected patients: 48-week results of the KIRAL study
por: Troya, Jesús, et al.
Publicado: (2018)

Factors associated with viral rebound among COVID-19 patients receiving oral antivirals
por: Chen, Pao-Yu, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_b8sk43aqaa1fob9dl4nm9lsk7i